Phaseline

Companies › E-Star BioTech

E-Star BioTech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MANP
Modified atrial natriuretic peptide
NPRAPhase 2Difficult to Control HypertensionJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06343298MANPPhase 2Difficult to Control HypertensionCardiovascularJul 2027

Targets

NPRA (1)

Companies with the same targets

–

Companies built like this

Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.